1. Aghajanian GK, Bunney BS. Central dopaminergic neurons: neurophysiological identification and response to drugs. In: Usdin E, Snyder SH, eds. Frontiers of catecholamine research. New York: Pergamon Press, 1973;643–648.

2. Aghajanian GK, Bunney BS. Pre- and postsynaptic feedback mechanisms in central dopaminergic neurons. In: Seeman P, Brown GM, eds. Frontiers of neurology and neuroscience research. Toronto: University of Toronto Press, 1974;4–11.

3. Bayer VE, Towle AC, Pickel VM. Ultrastructural localization of neurotensin-like immunoreactivity within dense core vesicles in perikarya, but not terminals, colocalizing tyrosine hydroxylase in the rat ventral tegmental area. J Comp Neurol 1991;311:179–196.

4. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 1981;212:51–57.

5. Bouthenet ML, Souil E, Matres MP, Sokoloff P, Giros B, Schwartz JC. Localisation of dopamine D3 receptor mRNA in the rat brain using in situ hybridisation histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 1991;564:203–219.

6. Breitwieser GE. G protein-mediated ion channel activation. Hypertension 1991;17:684–692.

7. Brodie MS, Dunwiddie TV. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro. Brain Res 1987;425:106–113.

8. Bunzow JR, VanTol HHM, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988;336:783–787.

9. Carlsson A. Dopaminergic autoreceptors. In: Almgren O, Carlsson A, Engel J, eds. Chemical tools in catecholamine research, vol 11. Amsterdam: North-Holland, 1975;219–224.

10. Castellano MA, Liu L-X, Monsma FJ Jr, Sibley DR, Kapatos G, Chiodo LA. Transfected D2 short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma {ewc MVIMG, MVIMAGE,!times.bmp} glioma hybrid (NG108-15) cells. Mol Pharmacol 1993;44:649–656.

11. Castelletti L, Memo M, Missale C, Spano PF, Valerio A. Potassium channels involved in the transduction mechanism of dopamine D-2 receptor in rat lactotrophs. J Physiol (Lond) 1989;410:251–265.

12. Chiodo LA, Bannon MJ, Grace AA, Roth RH, Bunney BS. Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of midbrain dopamine neurons. Neuroscience 1984;12:1–16.

13. Chiodo LA. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci Biobehav Rev 1988;12:49–90.

14. Chiodo LA, Kapatos G. Mesencephalic dopamine-containing neurons in culture: morphological and electrophysiological characterization. In: Chiodo LA, Freeman AS, eds. Neurophysiology of dopamine neuronal systems—current status and clinical perspectives. Grosse Pointe, MI: Lakeshore Publishing Co., 1987;67–91.

15. Chiodo LA. Dopamine autoreceptor signal transduction in the DA cell body: a "current" view. Neurochem Int 1992;20:18S–84S.

16. Chiodo LA, Freeman AS, Bunney BS. Electrophysiological studies on the specificity of the cholecystokinin antagonist proglumide. Brain Res 1987;410:205–211.

17. Chiodo LA, Kapatos G. Membrane properties of identified mesencephalic dopamine neurons in primary dissociated cell culture. Synapse 1992;11:294–309.

18. Chiodo LA, Liu L-X, Kapatos G. Goa mediates transduction of DA autoreceptor modulation of three different K+ currents. Soc Neurosci Abstr 1992;18:1516.

19. Chiodo LA, Liu L-X, Monsma FJ Jr, Sibley DR. Transfected D3 dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma {ewc MVIMG, MVIMAGE,!times.bmp} glioma hybrid (NG108-15) cells. Soc Neurosci Abstr 1993;19:79.

20. Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, Shiver BD, Seeburg PH. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J 1989;8:4025–4034.

21. Dockray GJ. Cholecystokinin in rat cerebral cortex: identification, purification and characterization by immunochemical methods. Brain Res 1980;188:155–165.

22. Freeman AS, Chiodo LA, Lentz S, Wade K, Bannon MJ. Release of CCK from midbrain slices and modulatory influence of D2 DA receptor stimulation. Brain Res 1991;555:281–287.

23. Freedman JE, Weight FF. Quinine potently blocks single K+ channels activated by dopamine D-2 receptors in rat corpus striatum. Eur J Pharmacol 1989;164:341–346.

24. Galloway MP, Wolf ME, Roth RH. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. J Pharmacol Exp Ther 1986;236: 689–698.

25. Gandelman KY, Harmon S, Todd RD, O'Malley KL. Analysis of the structure and expression of human dopamine D2A receptor gene. J Neurochem 1991;56:1024–1029.

26. Giros B, Sokoloff P, Matres MP, Riou JF, Emorine LJ, Schwartz JC. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 1989;343:923–926.

27. Grace AA. The regulation of dopamine neurons as determined by in vivo and in vitro intracellular recordings. In: Chiodo LA, Freeman AS, eds. Neurophysiology of dopamine neuronal systems—current status and clinical perspectives. Grosse Pointe, MI: Lakeshore Publishing Co., 1987;1–66.

28. Grace AA, Onn S-P. Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 1989;9:3463–3481.

29. Hökfelt T, Everitt BJ, Theodorsson-Norheim E, Goldstein M. Occurrence of neurotenson-like immunoreactivity in subpopulations of hypothalamic, mesencephalic and medullary catecholamine neurons. J Comp Neurol 1984;222:543–559.

30. Hökfelt T, Skirboll L, Rehfeld JF, Goldstein M, Markey K, Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 1980;5:2093–2124.

31. Hommer DW, Palkovits M, Crawley JN, Paul SM, Skirboll LR. Cholecystokinin-induced excitation in the substantia nigra: evidence for peripheral and central components. J Neurosci 1985;6:1387–1392.

32. Hommer DW, Skirboll LR. Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons. Eur J Pharmacol 1983;91:151–152.

33. Hommer DW, Stoner G, Crawley JN, Paul SM, Skirboll LR. Cholecystokinin-dopamine coexistence: electrophysiological actions corresponding to cholecystokinin receptor subtype. J Neurosci 1986;6:3039–3043.

34. Innis RB, Aghajanian GK. Pertussis toxin blocks autoreceptormediated inhibition of dopaminergic neurons in rat substantia nigra. Brain Res 1987;411:139–143.

35. Jennes L, Stumpf WE, Kalivas PW. Neurotensin: topographical distribution in rat brain by immunocytochemistry. J Comp Neurol 1982;210:211–224.

36. Kelland MD, Chiodo LA, Freeman AS. Receptor selectivity of cholecystokinin effects on mesoaccumbens dopamine neurons. Synapse 1991;8:137–143.

37. Kurachi Y, Tung RT, Ito H, Nakajima T. G protein activation of cardiac muscarinic K+ channels. Prog Neurobiol 1992;39:229–246.

38. Lacey MG, Mercuri NB, North RA. Dopamine acts on D2 receptors to increase potassium conductances in neurones of the rat substantia nigra zona compacta. J Physiol 1987;392:397–416.

39. Liu L-X, Kapatos G, Chiodo LA. Voltage-clamp analysis of calcium-dependent inward currents in cultured mesencephalic dopamine neurons. Soc Neurosci Abstr 1991;17:1350.

40. Liu L-X, Kapatos G, Chiodo LA. DA autoreceptor modulation of different calcium currents in DA neurons. Soc Neurosci Abstr 1992;18:1516.

41. Liu L-X, Monsma FJ Jr, Sibley DR, Chiodo LA. Coupling of D2-long receptor isoform to K+ currents in neuroblastoma {ewc MVIMG, MVIMAGE,!times.bmp} glioma (NG108-15) cells. Soc Neurosci Abstr 1993;19:79.

42. Liu L-X, Shen R-Y, Kapatos G, Chiodo LA. Dopamine neuron membrane physiology: characterization of the transient outward current (IA) and demonstration of a common signal transduction pathway for IA and IK. Synapse 1994;[in press].

43. Login IS, Pancrazio JJ, Kim YI. Dopamine enhances a voltage-dependent transient K+ current in the MMQ cell, a clonal pituitary line expressing functional D2 dopamine receptors. Brain Res 1990;506:331–334.

44. Man-Son-Hing H, Codina J, Abramowitz J, Haydon PG. Microinjection of the a-subunit of the G protein Go2, but not Go1, reduces a voltage-sensitive calcium current. Cell Signaling 1992;4:429–441.

45. Monsma FJ, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989;342:926–929.

46. Moran TH, Robinson PH, Goldrich MS, McHugh PR. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 986;62:175–179.

47. Neve KA, Henningsen RA, Bunzow JR, Civelli O. Functional characterization of a rat dopamine D-2 receptor cDNA expressed in a mammalian cell line. Mol Pharmacol 1989;36:446–451.

48. Neve KA, Neve RL, Fidel S, Janowsky A, Higgins GA. Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. Proc Natl Acad Sci USA 1991;88:2802–2806.

49. O'Malley KL, Mack KJ, Gandelman KY, Todd RD. Organization and expression of the rat D2A receptor gene: identification of alternative transcripts and a variant donor splice site. Biochemistry 1990;29:1367–1371.

50. Rehfeld JF. Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the central nervous system and small intestine of man and hog. J Biol Chem 1978;253:4022–4030.

51. Roeper J, Hainsworth AH, Ashcroft FM. Tolbutamide reverses membrane hyperpolarization induced by activation of D2 receptors and GABAB receptors in isolated substantia nigra neurones. Eur J Pharmacol 1990;416:473–475.

52. Seroogy KB, Ceccatelli S, Schalling M, Hökfelt T, Frey P, Dockray G, Buchan A, Goldstein M. A subpopulation of dopaminergic neurons in the rat ventral mesencephalon contain both neurotensin and cholecystokinin. Brain Res 1988;455:88–98.

53. Seroogy KB, Dangaran K, Lim S, Haycock JW, Fallon JH. Ventral mesencephalic neurons containing cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J Comp Neurol 1989;279:397–414.

54. Seroogy K, Schalling M, Brene S, Dagerlind A, Chai SY, Hökfelt T, Persson H, Brownstein M, Huan R, Dixon J, Filer D, Schlessinger D, Goldstein M. Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry. Exp Brain Res 1989;74:149–162.

55. Seutin V, Massotte L, Dresse A. Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro. Neuropharmacology 1989;28:949–954.

56. Shi W-X, Bunney BS. Neurotensin attenuates dopamine D2 agonist quinpirole-induced inhibition of midbrain dopamine neurons. Neuropharmacology 1990;29:1095–1097.

57. Shi W-X, Bunney BS. Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity. Brain Res 1991;543:315–321.

58. Shi W-X, Bunney BS. Roles of intracellular cAMP and protein kinase A in the actions of dopamine and neurotensin on midbrain dopamine neurons. J Neuroscience 1992;12:2433–2438.

59. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992;13:61–69.

60. Sibley DR. Cloning of a D3 receptor subtype expands dopamine receptor family. Trends Pharmacol Sci 1991;12:7–9.

61. Silva NL, Bunney BS. Intracellular studies of dopamine neurons in vitro: pacemakers modulated by dopamine. Eur J Pharmacol 1988;149:307–315.

62. Silva NL, Barker JL. Calcium currents recorded from nigrostriatal dopamine neurons acutely dissociated from the postnatal rat. Soc Neurosci Abstr 1989;15:1001.

63. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146–151.

64. Snyder LA, Roberts JL, Sealfon SC. Distribution of D2 receptor mRNA splice variants in the rat by solution hybridization/protection assay. Neurosci Lett 1991;122:37–40.

65. Sternweis PC, Pang IH. The G protein-channel connection. Trends Neurosci 1990;13:122–126.

66. Stittsworth JD, Mueller AL. Cholecystokinin octapeptide potentiates the inhibitory response mediated by D2 dopamine receptors in slices of the ventral tegmental area of the brain of the rat. Neuropharmacology 1990;29:119–127.

67. Szabo G, Otero AS. G protein mediated regulation of K+ channel in heart. Annu Rev Physiol 1990;52:293–305.

68. Woulfe J, Beaudet A. Neurotensin terminals form synapses primarily with neurons lacking tyrosine hydroxylase immunoreactivity in the rat substantia nigra and ventral tegmental area. J Comp Neurol 1992;321:163–176.

Back to Chapter